According to investigators, the existing NIH definition of interstitial inflammation in the kidneys of patients with lupus nephritis needs to be modified to account for inflammation in areas with and without fibrosis.
Prophylaxis against Pneumocystis jirovecii pneumonia with trimethoprim-sulfamethoxazole reduced the risk for severe infections by nearly 77%, a study found.
Sclerotic class biopsy and serum creatinine levels at baseline, the end of induction, and after 12 months of treatment emerge as the best prognostic factors for advanced CKD.
The slow clinical adoption of sodium-glucose cotransporter-2 inhibitors may partly be due to concerns about potential adverse effects, investigators suggested.
